Abstracts tagged "ANA"

Abstract Number: 2809 • 2016 ACR/ARHP Annual Meeting
Comparative Analysis of Anti-Nuclear Antibody Testing Using Blinded Replicate Samples Reveals Variability Between Commercial Testing Laboratories
Marc Chevrier, Jarrat Jordan, Jessica Schreiter and Jacqueline Benson, Estrela Lupus Venture, Janssen Research and Development, LLC., Spring House, PA
Background/Purpose: Serological positivity defined by presence of anti-nuclear antibodies (ANA) is frequently used in interventional lupus trials as an inclusion criterion and longitudinal biomarker. As such,…
Abstract Number: 2814 • 2016 ACR/ARHP Annual Meeting
Immunofluorescence Pattern and Titer of the Antinuclear Antibody Test Correlate with Disease Activity in Patients with Systemic Lupus Erythematosus
Mônica Simon Prado¹, Alessandra Dellavance², Sílvia H. Rodrigues³ and Luis Eduardo C. Andrade^4,5, ¹Rheumatology, Escola Paulista de Medicina, Universidade Federal de São Paulo, UNIFESP-EPM, São Paulo, Brazil, ²Research and Development Department, Fleury Medicine and Health Laboratories, São Paulo, Brazil, ³Rheumatology Division, Escola Paulista de Medicina, Universidade Federal de São Paulo, UNIFESP-EPM, Sao Paulo, Brazil, ⁴Rheumatology, Escola Paulista de Medicina, Universidade Federal de São Paulo, UNIFESP-EPM, Sao Paulo, Brazil, ⁵Fleury Health and Medicine, Sao Paulo, Brazil
Background/Purpose: Antinuclear antibody (ANA) indirect immunofluorescence (IIF) assay on HEp-2 cells (HEp-2-ANA) is an important element for diagnosis and classification of Systemic Lupus Erythematosus (SLE),…
Abstract Number: 2918 • 2016 ACR/ARHP Annual Meeting
The Clinical Relevance of Common ANA Patterns in Systemic Sclerosis
Ashraf Raslan¹, Clifford Stermer² and Vivien Hsu³, ¹Medicine, Rutgers-RWJ Medical School, Jersey City, NJ, ²Medicine, Rutgers-RWJMS, New York, NY, ³Rheumatology, RWJ Med Schl Scleroderma Prog, New Brunswick, NJ
Background/Purpose: Antinuclear antibody (ANA) test is positive in nearly 95% of patients with systemic sclerosis (SSc) [1]. We aim to identify the clinical relevance of…
Abstract Number: 443 • 2016 ACR/ARHP Annual Meeting
Repetitive Requisition of Antinuclear Antibody Testing (ANA) in Outpatient Multispecialty Clinics in Patients with a Known Positive ANA
Laura Amorese-O'Connell¹, Pinky Vaidya², Durkhani Mahboob², Charis Gn³ and Stuart Schwartz⁴, ¹Rheumatology, Brown University, RI hospital, Providence, RI, ²Rheumatology, Roger Williams Medical Center, Providence, RI, ³Internal Medicine, Rhode Island Hospital, The Warren Alpert Medical School of Brown University, Providence, RI, ⁴Brown Medical School, Providence, RI
Background/Purpose: Methods: Retrospective chart review was performed on 598 patients who underwent ANA testing between April 1st, 2015 and March 31st, 2016. Data collected…
Abstract Number: 797 • 2016 ACR/ARHP Annual Meeting
Randomized Clinical Trials of Systemic Lupus Erythematosus: Evaluating Differences in the Enrolled Populations
Niti Goel^1,2, Brandon Barrett³, Ann Duncan⁴, Margaret-Beth Gallagher¹ and Marsha Mackey³, ¹Quintiles, Inc., Durham, NC, ²Duke University School of Medicine, Durham, NC, ³Quintiles, Inc., Rockville, MD, ⁴Quintiles, Inc., Reading, Berkshire, United Kingdom
Background/Purpose: Background/Purpose: Randomized controlled trials (RCTs) in SLE identify specific populations of interest for eligibility, but still vary in the recruited populations. These differences may…
Abstract Number: 1047 • 2016 ACR/ARHP Annual Meeting
Negative Results of Antinuclear Antibody (ANA) Testing in Clinical Trials of Systemic Lupus Erythematosus (SLE) May be Due to Assay Variability
David Pisetsky¹, Dana Thompson¹, Joseph Wajdula², Annette Diehl² and Sudhakar Sridharan³, ¹Duke University Medical Center and Durham VAMC, Durham, NC, ²Global Product Development, Pfizer Inc, Collegeville, PA, ³PPD Inc, Rockville, MD
Background/Purpose: SLE clinical trials typically require that patients have either a positive ANA serology at a central laboratory during screening or have prior positive…
Abstract Number: 1049 • 2016 ACR/ARHP Annual Meeting
High Titer ANA Not Necessarily a Valid Criterion for Lupus – Proposal of a Modification to the Criteria for Classification of SLE
Luis E C Andrade¹, Jan Damoiseaux², Minoru Satoh³, Edward K.L. Chan⁴, Mônica Prado⁵, Henrique Mariz⁶, Renan Agustinelli⁷ and Alessandra Dellavance⁸, ¹Pediatric Rheumatology Unit, Universidade Federal de São Paulo, São Paulo, Brazil, ²Central Diagnostic Laboratory, Maastricht University Medical Center, Maastricht, Netherlands, ³Department of Clinical Nursing, School of Health Sciences, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁴Dept of Oral Biology, University of Florida, Gainesville, FL, ⁵Rheumatology, Escola Paulista de Medicina - Universidade Federal de São Paulo, Sao Paulo, Brazil, ⁶Internal Medicine, Hospital das Clínicas - UFPE, Recife, Brazil, ⁷Rheumatology Division, Escola Paulista de Medicina, São Paulo, Brazil, ⁸Research and Development Department, Fleury Medicine and Health Laboratories, São Paulo, Brazil
Background/Purpose: A positive ANA test is one of ACR Revised Criteria for Classification of SLE, as well as the SLICC classification. The ANA test provides…
Abstract Number: 1346 • 2016 ACR/ARHP Annual Meeting
Factors That Influence Therapy in Patients with Undifferentiated Connective Tissue Disease
Diana P. Pena¹ and Anca D. Askanase², ¹Rheumatology, Universidad Militar Nueva Granada, Bogotá, Colombia, ²Department of Medicine, Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY
Background/Purpose: To compare clinical and immunological characteristics in patients with undifferentiated connective tissue disease (UCTD) treated with hydroxycholoroquine (HCQ) in a large academic clinical practice.…
Abstract Number: 1769 • 2016 ACR/ARHP Annual Meeting
Fatigue in Anti-Nuclear Antibody Positive Individuals with Insufficient Criteria to Diagnose a Systemic Autoimmune Rheumatic Disease
Rawad Nori¹, Babak Noamani², Dennisse Bonilla², Larissa Lisnevskaia³, Earl Silverman⁴, Arthur Bookman⁵, Sindhu R. Johnson¹, Carolina Landolt-Marticorena² and Joan Wither², ¹Rheumatology, Mount Sinai Hospital and University Health Network, Toronto, ON, Canada, ²Krembil Research Institute, University Health Network, Toronto, ON, Canada, ³Lakeridge Health Services, Oshawa, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada, ⁵Rheumatology, University Health Network, Toronto, ON, Canada
Background/Purpose: Fatigue is a common symptom of Systemic Autoimmune Rheumatic Disease (SARD) and has been proposed to result from the elaboration of pro-inflammatory factors in…
Abstract Number: 773 • 2015 ACR/ARHP Annual Meeting
Clinical Evaluation of Patients with Positive Antibodies to Extractable Nuclear Antigens but Negative ANA
Megan L. Krause¹, Michael Ettore², Melissa R. Snyder³, Cynthia S. Crowson⁴ and Kevin G. Moder¹, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, ³Laboratory Medicine, Mayo Clinic, Rochester, MN, ⁴Health Sciences Research, Mayo Clinic, Rochester, MN
Background/Purpose: In the setting of a negative ANA, antibodies to extractable nuclear antigens (ENA) should be correspondingly negative, but alternative clinical scenarios occasionally arise. This…
Abstract Number: 774 • 2015 ACR/ARHP Annual Meeting
Anti-Nuclear Antibodies Have High Sensitivity for Systemic Lupus Erythematosus: Results of a Systematic Literature Review and Meta-Regression of Diagnostic Data
Nicolai Leuchten¹, Ralph Brinks², Annika Hoyer³, Monika Schoels⁴, Martin Aringer¹, Sindhu R. Johnson⁵, David I. Daikh⁶, Thomas Dorner⁷, George Bertsias⁸ and on behalf of the SLE Classification Criteria Steering Committee, ¹Medicine III, University Medical Center and Faculty of Medicine at the TU Dresden, Dresden, Germany, ²Hiller Center for Research in Rheumatology, Duesseldorf, Germany, ³Institute for Biometry and Epidemiology, German Diabetes Center, Duesseldorf, Germany, ⁴2nd Department of Medicine, Hietzing Hospital, Vienna, Austria, ⁵Dept of Rheumatology, Toronto Western and Mt. Sinai Hospitals, University of Toronto, Toronto, ON, Canada, ⁶Rheumatology, UCSF/VA Medical Center, San Francisco, CA, ⁷Charité University Medicine Berlin, Berlin, Germany, ⁸Rheumatology, Clinical Immunology, and Allergy, University of Crete, Heraklion, Greece
Background/Purpose: EULAR and ACR have jointly funded a project to improve existing SLE classification criteria, aiming at earlier and more accurate classification of the disease.…
Abstract Number: 776 • 2015 ACR/ARHP Annual Meeting
Sensitivity of Antinuclear Antibody By Immunofluorescence Testing for Detection of Anti-Ro/SSA Antibodies
Ivan Alcantara-Arreola¹, Nina Tello-Winniczuk² and Alejandro Diaz-Borjon³, ¹Hospital Angeles Lomas, Huixquilucan, Mexico, ²Division of Internal Medicine / Rheumatology, Hospital Angeles Lomas, Huixquilucan, Mexico, ³Med/Div of Rheumatology, Hospital Angeles Lomas, Huixquilucan, Mexico
Background/Purpose: A positive ANA test is a diagnostic criterion for several rheumatic diseases, although it may appear in other autoimmune disorders and healthy individuals. An…
Abstract Number: 777 • 2015 ACR/ARHP Annual Meeting
SLE-KeyTM Rule-out Test to Assess Lupus in Anti-Nuclear Antibody Positive Subjects Using the Immunarray iCHIP®
D. Scott Batty¹, I.R. Cohen², Chaim Putterman³, Nicole Jordan⁴, Keren Jakobi⁵, Rachel Sorek⁵, Yakov Blumenstein⁵, Pennina Safer⁵ and David Pisetsky⁶, ¹ImmunArray Inc., Richmond, VA, ²Weizmann Institute of Science, Rehovot, Israel, ³Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ⁴Montefiore Medical Center, New York, NY, ⁵ImmunArray LTD, Rehovot, Israel, ⁶Duke University Medical Center and Durham VAMC, Durham, NC
Background/Purpose: SLE is associated with a broad spectrum of autoantibodies, but currently there is no single serologic test to diagnose SLE definitively. Diagnosis is thus…
Abstract Number: 1122 • 2015 ACR/ARHP Annual Meeting
B Cell Phenotypic Changes in Anti-Nuclear Antibody Positive Individuals Prior to the Onset of Systemic Autoimmune Rheumatic Disease
Joan Wither¹, Nan-Hua Chang¹, Babak Noamani², Dennisse Bonilla¹, Sindhu R. Johnson³, Larissa Lisnevskaia⁴, Earl Silverman⁵, Arthur Bookman¹ and Carolina Landolt-Marticorena¹, ¹University Health Network, Toronto, ON, Canada, ²Genetics and developmental biology, University Health Network, Toronto, ON, Canada, ³Toronto Scleroderma Program, Toronto Western Hospital, Mount Sinai Hospital, University of Toronto, University Health Network Pulmonary Hypertension Programme, Toronto, ON, Canada, ⁴Lakeridge Health Services, Oshawa, ON, Canada, ⁵The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Patients with systemic autoimmune rheumatic diseases (SARD) often have a prolonged pre-clinical phase during which they are anti-nuclear antibody (ANA)+ but lack clinical symptoms. …
Abstract Number: 1376 • 2015 ACR/ARHP Annual Meeting
Presence of the Interferon Signature in Anti-Nuclear Antibody Positive Individuals Prior to the Onset of Systemic Autoimmune Rheumatic Disease
Joan Wither¹, Tony Liu¹, Babak Noamani², Dennisse Bonilla¹, Sindhu R. Johnson³, Earl Silverman⁴, Arthur Bookman¹, Larissa Lisnevskaia⁵ and Carolina Landolt-Marticorena¹, ¹University Health Network, Toronto, ON, Canada, ²Genetics and developmental biology, University Health Network, Toronto, ON, Canada, ³Toronto Scleroderma Program, Toronto Western Hospital, Mount Sinai Hospital, University of Toronto, University Health Network Pulmonary Hypertension Programme, Toronto, ON, Canada, ⁴The Hospital for Sick Children, Toronto, ON, Canada, ⁵Lakeridge Health Services, Oshawa, ON, Canada
Background/Purpose: Patients with systemic autoimmune rheumatic diseases (SARD) often have a prolonged pre-clinical phase during which they are anti-nuclear antibody (ANA)+ but lack clinical symptoms. …

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].